催化剂诱导的毒性:超越UGT1A1的药物遗传研究
Mirjam de With1,2, Leni van Doorn1, Esmay Kloet1
1Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
Clinical pharmacokinetics
|September 16, 2023
概括
这项研究研究了氨基酸代谢基因和毒性的单核酸多态性 (SNPs). 某些ABCG2和CES1SNP可以预测虹素诱导的毒性,有助于个性化癌症治疗策略.
科学领域:
- 药物基因组学 药物基因组学
- 在瘤学瘤学.
- 药物新陈代谢 药物新陈代谢
背景情况:
- 氨酸治疗与剂量限制的副作用有关,影响患者的生活质量.
- 了解影响氨酸代谢和运输的遗传因素对于管理毒性至关重要.
- 专注于碳乙酶 (CES) 和药物载体,超出UGT1A1,在氨酸代谢中.
研究的目的:
- 为了研究单核酸多态性 (SNPs) 之间的相关性,在氨酸代谢和运输基因和氨酸相关的毒性.
- 识别潜在的基因标记物,用于预测氨酸诱导的不良事件.
主要方法:
- 在CES1,CES2,SLCO1B1,ABCB1,ABCC2和ABCG2基因中的15个SNP的基因定型,在参与Code Geno或IRI28研究的患者中进行.
- 在299名可评估患者中分析了与虹素相关的毒性.
- 统计分析以确定SNP与毒性之间的关联,包括赔率比率和置信区间.
主要成果:
- 28.8%的患者经历了与色素相关的严重毒性.
- ABCG2 c.421C>A变异性等位基因携带者显示有毒性风险显著增加 (OR 1.88).
- CES1变种 (c.1165-41C>T和n.95346T>C) 与较低的血小板缺血风险有关.
结论:
- 在ABCG2和CES1基因中的单核酸多态 (SNPs) 可能作为预测性标记物来预测虹膜诱导的毒性.
- 这些发现可能有助于在氨酸治疗中的个性化医疗方法.
- 需要进一步的研究来验证这些遗传标记在临床实践中是否有效.
更多相关视频
相关概念视频
Nonlinear Pharmacokinetics: Role of Transporters
72
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
72
Phase II Reactions: Glucuronidation
504
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
504
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
Factors Affecting Drug Biotransformation: Biological
177
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
177
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
192
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
192
Phase II Reactions: Miscellaneous Conjugation Reactions
81
Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
81


